NCT00992147 is a Phase 2/Phase 3 clinical trial of Adipocell in Depressed Scar, sponsored by Anterogen Co., Ltd..

Who is sponsoring NCT00992147?

NCT00992147 is sponsored by Anterogen Co., Ltd..

What drugs are being tested in NCT00992147?

Interventions in NCT00992147: Adipocell.

What condition does NCT00992147 study?

NCT00992147 studies Depressed Scar.

Is NCT00992147 still recruiting?

NCT00992147 is currently completed. Last updated 8 October 2009.

Last reviewed 2009-10-08 · How we verify

NCT00992147

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II/III Clinical Study of ANTG-adip for the Treatment of Depressed Scar to Evaluate Safety and Efficacy

Completed Phase 2/Phase 3 Last updated 8 October 2009

What this trial tests

Phase 2/Phase 3 trial testing Adipocell in Depressed Scar in 36 participants. Completed in 1 March 2007.

Timeline

1 May 2004

1 March 2007

Quick facts

Lead sponsor	Anterogen Co., Ltd.
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 May 2004
Estimated completion	1 March 2007
Sites	1 location across South Korea

Drugs / interventions tested

Adipocell — full drug profile →

Conditions studied

Depressed Scar — all drugs for Depressed Scar →

Sponsor

Anterogen Co., Ltd. — full company profile →

Who can join

19 and older, any sex, with Depressed Scar. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Efficacy: recovery rate(%)
Time frame: week 12
Safety: clinically measured abnormality of laboratory tests and adverse events, Injection site observation, Immune rejection test

Sponsor's own description

Autologous cultured adipocytes (ANTG-adip) is produced by well-established techniques including cell harvesting from lipoaspirates, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. This was an open-label, dose-escalation study. Patients are given subcutaneous injection of ANTG-adip and followed for 12 weeks according to the clinical trial protocol.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Adipose-Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications.
Dai R, Wang Z, Samanipour R, Koo KI, et al · · 2016 · cited 191× · PMID 27057174 · DOI 10.1155/2016/6737345
Adipose-derived stromal cells: Their identity and uses in clinical trials, an update.
Casteilla L, Planat-Benard V, Laharrague P, Cousin B. · · 2011 · cited 162× · PMID 21607134 · DOI 10.4252/wjsc.v3.i4.25
Mesenchymal Stem Cells from Adipose Tissue in Clinical Applications for Dermatological Indications and Skin Aging.
Gaur M, Dobke M, Lunyak VV. · · 2017 · cited 105× · PMID 28117680 · DOI 10.3390/ijms18010208

Verify or expand the search:

Other Anterogen Co., Ltd. trials

Trials by the same sponsor.

NCT06539429 — Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L · Phase 1 · active not recruiting
NCT05157958 — Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa · Phase 2 · recruiting
NCT06141811 — A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial · recruiting
NCT04569409 — Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers. · Phase 3 · completed
NCT04590703 — A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00992147 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anterogen Co., Ltd.
Last refreshed: 8 October 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00992147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing